{"id": "qHBAJ2T5cs5U", "question_type": "open_ended_multi_choice", "question": "A 10-year-old child diagnosed with juvenile rheumatoid arthritis (JRA) requires treatment. Genetic testing reveals the child is a poor CYP2C9 metabolizer. Which drug is the most appropriate for this patient?", "options": {"A": "Celecoxib 200 mg", "B": "First Aid Direct Chewable Aspirin", "C": "Florexa", "D": "None of the above"}}
{"id": "tvnSoQOIv0R0", "question_type": "multi_choice", "question": "What was the purpose of the 6-month study conducted in CD-1 mice using cV1q anti-mouse TNFα, an analogous antibody to REMICADE?", "options": {"A": "To study the effects of REMICADE on cardiovascular health.", "B": "To evaluate the pharmacokinetics of REMICADE in mice.", "C": "To assess the tumorigenic potential of cV1q anti-mouse TNFα.", "D": "To determine the optimal dosage of REMICADE for mice."}}
{"id": "geKGSRnr3ZvM", "question_type": "open_ended", "question": "When switching a patient from another pancreatic enzyme product to PERTZYE, what is the recommended approach?", "options": {"A": "Directly substitute the products without monitoring.", "B": "Monitor for clinical symptoms of exocrine pancreatic insufficiency and titrate the dosage as needed.", "C": "Start with the highest recommended dosage of PERTZYE.", "D": "Discontinue the previous product for 7 days before starting PERTZYE."}}
{"id": "BfT80HZMyjuo", "question_type": "multi_choice", "question": "What is the secondary benefit of the drug branded as 70% apart from preventing sunburn?", "options": {"A": "It treats sunburn after it occurs.", "B": "It reduces the risk of skin cancer and early skin aging caused by the sun.", "C": "It enhances the effectiveness of other skincare products.", "D": "It prevents skin dryness caused by sun exposure."}}
{"id": "QjaQymRAabrS", "question_type": "open_ended_multi_choice", "question": "A 45-year-old male patient with hemophilia is scheduled for a tooth extraction. He has a history of thromboembolic events and is currently using hormonal contraceptives. Which drug is the safest and most effective option to reduce hemorrhage during the procedure?", "options": {"A": "Tolterodine Tartrate", "B": "Tranexamic Acid", "C": "Gabapentin", "D": "None of the above"}}
{"id": "aVd9WMZiU1Uc", "question_type": "open_ended_multi_choice", "question": "A 30-year-old woman in her first trimester of pregnancy is diagnosed with a streptococcal skin infection. She has no history of allergies and is not currently breastfeeding. What is the safest medication to prescribe for her condition?", "options": {"A": "Clindamycin Phosphate", "B": "Ceftriaxone Sodium", "C": "Tetracycline", "D": "Ciprofloxacin"}}
{"id": "vdnOO7o0WeUw", "question_type": "open_ended", "question": "A 35-year-old pregnant woman with heterozygous familial hypercholesterolemia (HeFH) is seeking treatment for high LDL-C levels. Which of the following is the most appropriate recommendation regarding ZOCOR (simvastatin) therapy?", "options": {"A": "Continue ZOCOR therapy at the current dose of 40 mg daily.", "B": "Switch to a lower dose of ZOCOR (10 mg daily).", "C": "Discontinue ZOCOR therapy immediately.", "D": "Increase ZOCOR dosage to 80 mg daily for better LDL-C control."}}
{"id": "sawz3MjTgBIC", "question_type": "open_ended_multi_choice", "question": "Considering a 32-year-old male patient with unresectable liposarcoma, congenital long QT syndrome, and ongoing use of QT-prolonging drugs, who has previously received an anthracycline-based therapy, what is the best treatment choice for his condition?", "options": {"A": "Halaven administered intravenously at 1.4 mg/m² every 21 days.", "B": "Halaven administered intravenously at 1.1 mg/m² every 21 days.", "C": "Alitretinoin gel applied topically twice daily.", "D": "No treatment with Halaven due to contraindications related to QT prolongation."}}
{"id": "QrbYTLNQW0Yx", "question_type": "open_ended_multi_choice", "question": "A 65-year-old male with mild Alzheimer's disease-related dementia is being evaluated for Kisunla therapy. His MRI shows no evidence of microhemorrhages or superficial siderosis, but he has a history of hypersensitivity reactions to monoclonal antibodies. What is the most appropriate management plan?", "options": {"A": "Initiate Kisunla treatment with pre-treatment using antihistamines and corticosteroids to manage hypersensitivity risks.", "B": "Avoid Kisunla treatment due to the patient's history of hypersensitivity reactions to monoclonal antibodies.", "C": "Switch to Donanemab-AZBT as it does not have hypersensitivity warnings.", "D": "Initiate Kisunla treatment without pre-treatment or monitoring for hypersensitivity reactions."}}
